The latest announcement is out from Prescient Therapeutics Limited ( (AU:PTX) ).
Prescient Therapeutics has achieved a significant milestone by opening the first clinical site for its PTX-100 Phase 2a study, targeting Cutaneous T-Cell Lymphoma. The company presented new clinical data at an international forum, highlighting PTX-100’s mechanism of action and safety profile. Financially, Prescient reported a cash balance of $10.2 million, bolstered by a $3.7 million R&D Tax Incentive Rebate. The company is also exploring collaborations to enhance cell therapy programs and has appointed Dr. James Campbell as the new Board Chair, succeeding Steven Engle.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized therapies for cancer. The company is involved in creating innovative treatments, particularly in the field of T-cell lymphoma, and is actively engaged in research and development to advance its therapeutic offerings.
YTD Price Performance: -2.00%
Average Trading Volume: 553,503
Technical Sentiment Signal: Hold
Current Market Cap: A$39.46M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.